183 related articles for article (PubMed ID: 30760451)
1. Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease.
Zhang L; Zhao AL; Duan MH; Li ZY; Cao XX; Feng J; Zhou DB; Zhong DR; Fajgenbaum DC; Li J
Blood; 2019 Apr; 133(16):1720-1728. PubMed ID: 30760451
[TBL] [Abstract][Full Text] [Related]
2. Dichotomic response to interleukin-6 blockade in idiopathic multicentric Castleman disease: two case reports.
Ferrero S; Ragaini S
J Med Case Rep; 2021 Mar; 15(1):105. PubMed ID: 33676575
[TBL] [Abstract][Full Text] [Related]
3. A prospective, multicenter study of bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory iMCD.
Zhang L; Zhang MY; Cao XX; Zhou DB; Fajgenbaum DC; Dong YJ; Li J
Leuk Lymphoma; 2022 Mar; 63(3):618-626. PubMed ID: 35100929
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of rituximab-containing treatment regimens in idiopathic multicentric Castleman disease.
Dong Y; Zhang L; Nong L; Wang L; Liang Z; Zhou D; Fajgenbaum DC; Ren H; Li J
Ann Hematol; 2018 Sep; 97(9):1641-1647. PubMed ID: 29732477
[TBL] [Abstract][Full Text] [Related]
5. Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease.
van Rhee F; Rosenthal A; Kanhai K; Martin R; Nishimura K; Hoering A; Fajgenbaum DC
Blood Adv; 2022 Aug; 6(16):4773-4781. PubMed ID: 35793409
[TBL] [Abstract][Full Text] [Related]
6. Idiopathic multicentric Castleman disease treated with siltuximab for 15 years: a case report.
Lang E; Sande B; Brodkin S; van Rhee F
Ther Adv Hematol; 2022; 13():20406207221082552. PubMed ID: 35251585
[TBL] [Abstract][Full Text] [Related]
7. The clinical, laboratory, and radiologic improvement due to siltuximab treatment in idiopathic multicentric Castleman's disease.
Min GJ; Jeon YW; Park SS; Park S; Shin SH; Yahng SA; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Kim DW; Lee JW; Cho SG
Korean J Intern Med; 2021 Mar; 36(2):424-432. PubMed ID: 32088937
[TBL] [Abstract][Full Text] [Related]
8. Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials.
van Rhee F; Casper C; Voorhees PM; Fayad LE; Gibson D; Kanhai K; Kurzrock R
Lancet Haematol; 2020 Mar; 7(3):e209-e217. PubMed ID: 32027862
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic experience of vincristine/cyclophosphamide/melphalan or mitoxantrone/prednisone combination therapy plus thalidomide as first-line induction therapy for newly diagnosed multiple myeloma in a single institution of China.
Wang X; He P; Guo C; Sun C; Zhang M
Asia Pac J Clin Oncol; 2017 Oct; 13(5):e408-e415. PubMed ID: 27739213
[TBL] [Abstract][Full Text] [Related]
10. Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study.
Larocca A; Montefusco V; Bringhen S; Rossi D; Crippa C; Mina R; Galli M; Marcatti M; La Verde G; Giuliani N; Magarotto V; Guglielmelli T; Rota-Scalabrini D; Omedé P; Santagostino A; Baldi I; Carella AM; Boccadoro M; Corradini P; Palumbo A
Blood; 2013 Oct; 122(16):2799-806. PubMed ID: 23954889
[TBL] [Abstract][Full Text] [Related]
11. Clinical features and treatment of 7 Chinese TAFRO syndromes from 96 de novo Castleman diseases: a 10-year retrospective study.
Zhang Y; Suo SS; Yang HJ; Zhou XP; You LS; Yu WJ; Wang ZM; Jin J
J Cancer Res Clin Oncol; 2020 Feb; 146(2):357-365. PubMed ID: 31938902
[TBL] [Abstract][Full Text] [Related]
12. Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data.
Morra DE; Pierson SK; Shilling D; Nemat S; Appiani C; Guilfoyle M; Tendler C; van Rhee F; Fajgenbaum DC
Br J Haematol; 2019 Jan; 184(2):232-241. PubMed ID: 30203839
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
14. Therapy of Castleman's disease with siltuximab - case report and review of literature.
Adam Z; Zeman D; Chodacki A; Pour L; Horváth T; Benda P; Adamová Z; Krejčí M; Tomíška M; Boichuk I; Král Z
Klin Onkol; 2023; 37(4):320-329. PubMed ID: 38195387
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Tolerance and Efficacy of Siltuximab (Anti-IL-6) in a Young Adult with Idiopathic Multicentric Castleman Disease During COVID-19.
Bedier H; Isnard S; Maedler-Kron C; Routy JP
Eur J Case Rep Intern Med; 2023; 10(12):004098. PubMed ID: 38077710
[TBL] [Abstract][Full Text] [Related]
16. Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial.
Vitolo U; Chiappella A; Franceschetti S; Carella AM; Baldi I; Inghirami G; Spina M; Pavone V; Ladetto M; Liberati AM; Molinari AL; Zinzani P; Salvi F; Fattori PP; Zaccaria A; Dreyling M; Botto B; Castellino A; Congiu A; Gaudiano M; Zanni M; Ciccone G; Gaidano G; Rossi G;
Lancet Oncol; 2014 Jun; 15(7):730-7. PubMed ID: 24831981
[TBL] [Abstract][Full Text] [Related]
17. Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma.
Reece DE; Masih-Khan E; Atenafu EG; Jimenez-Zepeda VH; Anglin P; Chen C; Kukreti V; Mikhael JR; Trudel S
Br J Haematol; 2015 Jan; 168(1):46-54. PubMed ID: 25146584
[TBL] [Abstract][Full Text] [Related]
18. A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease.
van Rhee F; Casper C; Voorhees PM; Fayad LE; van de Velde H; Vermeulen J; Qin X; Qi M; Tromp B; Kurzrock R
Oncotarget; 2015 Oct; 6(30):30408-19. PubMed ID: 26327301
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.
Hulin C; Facon T; Rodon P; Pegourie B; Benboubker L; Doyen C; Dib M; Guillerm G; Salles B; Eschard JP; Lenain P; Casassus P; Azaïs I; Decaux O; Garderet L; Mathiot C; Fontan J; Lafon I; Virion JM; Moreau P
J Clin Oncol; 2009 Aug; 27(22):3664-70. PubMed ID: 19451428
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.
Mateos MV; Oriol A; Martínez-López J; Gutiérrez N; Teruel AI; de Paz R; García-Laraña J; Bengoechea E; Martín A; Mediavilla JD; Palomera L; de Arriba F; González Y; Hernández JM; Sureda A; Bello JL; Bargay J; Peñalver FJ; Ribera JM; Martín-Mateos ML; García-Sanz R; Cibeira MT; Ramos ML; Vidriales MB; Paiva B; Montalbán MA; Lahuerta JJ; Bladé J; Miguel JF
Lancet Oncol; 2010 Oct; 11(10):934-41. PubMed ID: 20739218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]